Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The DNA mismatch repair pathway is a highly conserved multi-protein DNA repair mechanism that detects and corrects errors resulting from DNA replication, primarily base-base mismatches and small insertion-deletion loops. This pathway includes proteins such as MutS homologs (MSH2, MSH6, MSH3) that recognize DNA mismatches, and MutL homologs (MLH1, PMS2, PMS1, MLH3) that coordinate and execute excision and resynthesis of erroneous DNA segments. Proper function of the pathway is essential for preventing mutations and suppressing tumorigenesis, as loss or dysfunction leads to increased cancer risk and is a key feature of some hereditary cancer syndromes like Lynch syndrome.
For relevant drugs: Synthetic lethality in MMR-deficient tumors, or increased immune recognition due to high mutational burden in MMR-deficient cancers targeted by immunotherapy
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on DNA mismatch repair pathway (MMR pathway).